Verseon Corp. | Balance Sheet

Fiscal year is January-December. All values GBP Thousands.
2015
2016
2017
Cash & Short Term Investments
50,664.90
38,113.50
9,624.10
Other Current Assets
114.00
115.70
301.60
Total Current Assets
50,778.90
38,229.30
9,925.70
Net Property, Plant & Equipment
6,675.50
18,068.20
30,107.60
Total Investments and Advances
677.10
-
-
Total Assets
58,131.50
56,297.50
40,033.30
ST Debt & Current Portion LT Debt
148.60
-
-
Accounts Payable
-
-
3,301.40
Other Current Liabilities
1,090.30
3,736.50
1,406.00
Total Current Liabilities
1,238.90
3,736.50
4,707.40
Long-Term Debt
-
-
1,901.30
Total Liabilities
1,238.90
3,736.50
6,608.80
Common Equity (Total)
54,370.00
49,556.10
30,674.60
Total Shareholders' Equity
54,370.00
49,556.10
30,674.60
Total Equity
56,892.60
52,561.00
33,424.50
Liabilities & Shareholders' Equity
58,131.50
56,297.50
40,033.30
Accumulated Minority Interest
2,522.60
3,004.90
2,750.00

About Verseon

View Profile
Address
47071 Bayside Parkway
Fremont California 94538
United States
Employees -
Website http://www.verseon.com
Updated 09/14/2018
Verseon Corp. engages in the development and design of pharmaceutical products. It focuses on drug discovery technology to seed a growing portfolio of programs targeting diverse disease areas, currently consisting of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology. The company was founded by Eniko Fodor, David Kita, and Adityo Prakash in 2002 and is headquartered in Fremont, CA.